Search
Menu
Home
HTB
2024
August
August 2024
Contents
Conference reports
AIDS 2024: Ten early reports
Five days on two days off: Biktarvy in pilot FOTO study
Subcutaneous formulation of long-acting CAB/RPV discontinued
First data on third-generation integrase inhibitor from ViiV
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
Antiretrovirals
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
mpox
WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study
HTB RSS
Early access
Vaccination effectively limits mpox progression: lower efficacy in people living with HIV
27 May 2025
US update guidelines for statin use in people living with HIV
26 May 2025
HIV activists in the US call for action and Zachie Achmet brings South African perspective
26 May 2025
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
All early access reports
Current issues
May 2025
April 2025
March 2025
Back issues
Special report
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate